Rimonabant Meta-Analysis Reveals Increased Risk Of Psychiatric Events – The Lancet
Study introduces nothing new about the obesity drug that has not been discussed with regulatory authorities, Sanofi-Aventis responds to “The Pink Sheet” DAILY.
Study introduces nothing new about the obesity drug that has not been discussed with regulatory authorities, Sanofi-Aventis responds to “The Pink Sheet” DAILY.